Quantcast

Latest chronic pancreatitis Stories

2011-06-29 00:00:00

AMSTERDAM, June 29, 2011 /PRNewswire/ -- Data Presented at the 79th European Atherosclerosis Society Meeting Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today released data showing that its gene therapy Glybera(R) (alipogene tiparvovec) significantly reduces the risk of pancreatitis in patients with Lipoprotein Lipase Deficiency (LPLD). Pancreatitis, or...

2011-03-22 16:02:53

A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas. The findings of the study, funded by the Medical Research Council, could lead to the development of new treatments to reduce the chances of people developing pancreatic cancer. The protein, calmodulin, is involved in the basic processes that take place in all cells, the building blocks of the body. This study reveals that when calmodulin is missing from cells in the...

2011-03-11 15:31:03

The relative rate of alcohol-related chronic pancreatitis (CP) is lower when compared to other causes, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. Patients with no identifiable cause for their disease as well as those with non-alcohol-related causes represent an unexpectedly large subgroup, particularly among women. "One of the more remarkable observations is that in more than 50...

2011-01-12 16:04:00

INDIANAPOLIS, Jan. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to recommend non-approval of liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), currently under FDA review for the treatment of exocrine pancreatic insufficiency (EPI). During the meeting, the committee had questions about the degree of efficacy of liprotamase and recommended that...

2011-01-06 13:45:39

The use of combined treatments for severe acute pancreatitis is safe and effective in managing the disease, resulting in shorter hospitalizations and fewer radiological procedures than standard therapy, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. In a related study, doctors found that patients with infected pancreatic necrosis were able to avoid surgery through primary conservative...

2010-07-02 07:00:00

INDIANAPOLIS and CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT). Liprotamase is under review by the...

2010-05-27 05:00:00

WALTHAM, Mass., May 27 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read). The FDA and EMA have agreed to the Phase 3 re-read based on the numerous...

2010-05-03 13:22:40

Quality-of-life measures used routinely to assess treatment outcomes for patients with pancreatic disease may be used to predict both malignancy and survival for those patients, according to a study by Henry Ford Hospital. Researchers found that pre-treatment quality-of-life scores could predict malignancy in patients with pancreatic lesions and survival in those who are found to have malignancies. "Our findings suggest that pretreatment quality-of-life scores may show which patients will...

2010-05-03 07:02:00

ABBOTT PARK, Ill.., May 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas...

2010-04-12 16:30:00

SILVER SPRING, Md., April 12 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Pancreaze Delayed Release Capsules, a pancreatic enzyme product (PEP). It is the third such product to receive FDA approval. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) Pancreatic enzyme products improve food digestion in patients whose bodies do not produce enough pancreatic enzymes. This includes people who have conditions such as cystic fibrosis, chronic...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related